- Home
- MYGN vs RVT Comparison
MYGN vs RVT Comparison
Compare MYGN & RVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- RVT
- Stock Information
- Founded
- MYGN 1991
- RVT 1986
- Country
- MYGN United States
- RVT United States
- Employees
- MYGN N/A
- RVT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RVT Trusts Except Educational Religious and Charitable
- Sector
- MYGN Health Care
- RVT Finance
- Exchange
- MYGN Nasdaq
- RVT Nasdaq
- Market Cap
- MYGN 2.0B
- RVT 1.8B
- IPO Year
- MYGN 1995
- RVT N/A
- Fundamental
- Price
- MYGN $12.39
- RVT $16.32
- Analyst Decision
- MYGN Hold
- RVT
- Analyst Count
- MYGN 12
- RVT 0
- Target Price
- MYGN $23.92
- RVT N/A
- AVG Volume (30 Days)
- MYGN 1.0M
- RVT 243.4K
- Earning Date
- MYGN 02-25-2025
- RVT 01-01-0001
- Dividend Yield
- MYGN N/A
- RVT 7.32%
- EPS Growth
- MYGN N/A
- RVT N/A
- EPS
- MYGN N/A
- RVT 2.95
- Revenue
- MYGN $823,600,000.00
- RVT N/A
- Revenue This Year
- MYGN $13.82
- RVT N/A
- Revenue Next Year
- MYGN $4.59
- RVT N/A
- P/E Ratio
- MYGN N/A
- RVT $4.98
- Revenue Growth
- MYGN 12.15
- RVT N/A
- 52 Week Low
- MYGN $12.17
- RVT $11.85
- 52 Week High
- MYGN $29.30
- RVT $14.93
- Technical
- Relative Strength Index (RSI)
- MYGN 29.80
- RVT 60.06
- Support Level
- MYGN $12.17
- RVT $15.53
- Resistance Level
- MYGN $15.08
- RVT $16.20
- Average True Range (ATR)
- MYGN 0.79
- RVT 0.21
- MACD
- MYGN -0.01
- RVT 0.07
- Stochastic Oscillator
- MYGN 7.56
- RVT 90.80
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.